Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Zilli

Showing results (111-120 of 234) with videos related to

Pageof 24
Sort By:
Radiation Oncology (London, England)|August 10, 2012
Target volume definition in high-risk prostate cancer patients using sentinel node SPECT/CT and 18 F-choline PET/CTHansjörg Vees, Charles Steiner, Giovanna Dipasquale, et al.
Neurobiology of Aging|April 25, 2021
Treatment by low-dose brain radiation therapy improves memory performances without changes of the amyloid load in the TgF344-AD rat modelKelly Ceyzériat, Thomas Zilli, Aïda B Fall, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 29, 2009
Recurrence pattern after [(18)F]fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective studyDamien C Weber, Nathalie Casanova, Thomas Zilli, et al.
EJNMMI Research|December 14, 2018
First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist <sup>68</sup>Ga-NODAGA-MJ9Silvano Gnesin, Francesco Cicone, Periklis Mitsakis, et al.
Medical Oncology (Northwood, London, England)|June 14, 2019
Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRIVerane Achard, Giorgio Lamanna, Antoine Denis, et al.
Cancer Medicine|March 12, 2020
Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up resultsThomas Zilli, Sandra Jorcano, Samuel Bral, et al.
Prostate Cancer and Prostatic Diseases|April 8, 2024
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trialsMohamed Shelan, Vérane Achard, Felix Appiagyei, et al.
International Journal of Radiation Oncology, Biology, Physics|April 18, 2026
Metastasis-directed Therapy in Oligometastatic Castration-resistant Prostate Cancer: From Chasing the Last Metastasis to Changing the Game?Thomas Zilli, Nicholas G Zaorsky, Priyamvada Maitre, et al.
Revue Medicale Suisse|June 24, 2017
[Multidisciplinary management of localized rectal cancer]Nicolas C Buchs, Thibaud Koessler, Giulio C Vitali, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 10, 2025
Ultrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectivesMiguel Angel Berenguer-Frances, Abrahams Ocanto, Thomas Zilli, et al.
Pageof 24

Showing results (111-120 of 234) with videos related to

Sort By:
Pageof 24
Radiation Oncology (London, England)|August 10, 2012
Target volume definition in high-risk prostate cancer patients using sentinel node SPECT/CT and 18 F-choline PET/CTHansjörg Vees, Charles Steiner, Giovanna Dipasquale, et al.
Neurobiology of Aging|April 25, 2021
Treatment by low-dose brain radiation therapy improves memory performances without changes of the amyloid load in the TgF344-AD rat modelKelly Ceyzériat, Thomas Zilli, Aïda B Fall, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 29, 2009
Recurrence pattern after [(18)F]fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective studyDamien C Weber, Nathalie Casanova, Thomas Zilli, et al.
EJNMMI Research|December 14, 2018
First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist <sup>68</sup>Ga-NODAGA-MJ9Silvano Gnesin, Francesco Cicone, Periklis Mitsakis, et al.
Medical Oncology (Northwood, London, England)|June 14, 2019
Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRIVerane Achard, Giorgio Lamanna, Antoine Denis, et al.
Cancer Medicine|March 12, 2020
Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up resultsThomas Zilli, Sandra Jorcano, Samuel Bral, et al.
Prostate Cancer and Prostatic Diseases|April 8, 2024
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trialsMohamed Shelan, Vérane Achard, Felix Appiagyei, et al.
International Journal of Radiation Oncology, Biology, Physics|April 18, 2026
Metastasis-directed Therapy in Oligometastatic Castration-resistant Prostate Cancer: From Chasing the Last Metastasis to Changing the Game?Thomas Zilli, Nicholas G Zaorsky, Priyamvada Maitre, et al.
Revue Medicale Suisse|June 24, 2017
[Multidisciplinary management of localized rectal cancer]Nicolas C Buchs, Thibaud Koessler, Giulio C Vitali, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 10, 2025
Ultrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectivesMiguel Angel Berenguer-Frances, Abrahams Ocanto, Thomas Zilli, et al.
Pageof 24